Compare PIPR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIPR | CRSP |
|---|---|---|
| Founded | 1895 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 2003 | 2016 |
| Metric | PIPR | CRSP |
|---|---|---|
| Price | $72.86 | $54.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $91.38 | $70.29 |
| AVG Volume (30 Days) | 513.2K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | ★ 54.49 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,904,217,000.00 | $289,590,000.00 |
| Revenue This Year | $12.30 | $807.72 |
| Revenue Next Year | $13.55 | $172.52 |
| P/E Ratio | $78.58 | ★ N/A |
| Revenue Growth | 24.33 | ★ 9169.85 |
| 52 Week Low | $72.02 | $44.12 |
| 52 Week High | $380.26 | $78.48 |
| Indicator | PIPR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 54.17 |
| Support Level | N/A | $50.17 |
| Resistance Level | $82.43 | $60.10 |
| Average True Range (ATR) | 2.29 | 2.63 |
| MACD | -0.22 | 0.31 |
| Stochastic Oscillator | 5.90 | 61.87 |
Piper Sandler Cos is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States (U.S.) and internationally. The company provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. It generates maximum revenue from Advisory services followed by Equity financing.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.